Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study

References

• Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochem Pharmacol. 2016;101:27–39.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Akiyama N, Shiga T, et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int. 2015;6:125–138.
   Web of Science ®Google Scholar
• Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2014;17:304–308.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Kazuta K, Takinami Y, et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int. 2015;6:8–18.
   Web of Science ®Google Scholar
• Kashiwagi A, Kazuta K, Yoshida S, et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:382–391.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Shiga T, Akiyama N, et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int. 2015;6:104–116.
   Web of Science ®Google Scholar
• Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152–160.
   PubMed Web of Science ®Google Scholar
• Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6:533–542.
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Clinical Data Management Study Group. Results of data analysis 2013. 2013 [cited 2015 Dec 1]. Available from: http://jddm.jp/data/index-2013.html
   Google Scholar
• Terauchi Y, Yokote K, Nakamura I, et al. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17:463–471.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795–800.
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of technical requirements for registration of pharmaceuticals for human use. Medical Dictionary for Regulatory Activities Version 18.1; 2015; Geneva: International Council for Harmonisation of technical requirements for registration of pharmaceuticals for human use.
   Google Scholar
• IMS Health. JPM. 2016 Mar. MAT; Tokyo: IMS Health Japan Inc.
   Google Scholar
• Cha SA, Yun JS, Lim TS, et al. Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J. 2016;40:e7.
   Google Scholar
• Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18:135–141.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Tessier DM. Diabetes, dementia and hypoglycemia. Can J Diabetes. 2016;40:73–76.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Kachroo S, Kawabata H, et al. Association between hypoglycemia and fall-related fractures and health care utilization in older veterans with type 2 diabetes. Endocr Pract. 2016;22:196–204.
   PubMed Web of Science ®Google Scholar
• Gu W, Ren Y, Ji L, et al. Non-linear associations of risk factors with mild hypoglycemia among Chinese patients with type 2 diabetes. J Diabetes Complications. 2016;30:462–468.
   PubMed Web of Science ®Google Scholar
• Carter BL. Dosing of antihypertensive medications in patients with renal insufficiency. J Clin Pharmacol. 1995;35:81–86.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Duhme DW, Allen MD, et al. Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J. 1977;94:6–13.
   PubMed Web of Science ®Google Scholar
• Lowe J, Gray J, Henry DA, et al. Adverse reactions to frusemide in hospital inpatients. Br Med J. 1979;2:360–362.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Bode B, Harris S, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64:543–552.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37.
   PubMed Web of Science ®Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–484.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–1119.
   PubMed Web of Science ®Google Scholar
• Bohannon NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care. 1998;21:451–456.
   PubMed Web of Science ®Google Scholar
• Rudofsky G, Baldycheva I, Johnsson E, et al. Genital infections and relation to body mass index in patients with type 2 diabetes mellitus treated with dapagliflozin. Diabetologia. 2015;58:759–P. Abstract
   Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–478.
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med. 2014;126:7–17.
   PubMed Web of Science ®Google Scholar